Christopher Bebbington BA, DPhil

Dr Bebbington co-founded Allakos in 2012. He has more than 30 years experience in the biopharmaceutical industry, developing platform technologies and antibodies for therapeutic development. He developed expression systems for biologics including the GS SystemTM at Celltech, novel antibody-conjugate technologies at Coulter Pharmaceuticals and Corixa, led the research team that developed antibody humaneeringTM at KaloBios, and has developed therapeutic antibodies for clinical development as founding CEO and CSO at Allakos.